Niewydolność serca z zachowaną frakcją wyrzutową lewej komory — rozpoznawanie i leczenie

Abstract

Heart faillure with preserved ejection fraction (HFpEF) is now the most common form of HF and accounts for about half the cases of the disease due to population ageing and the increasing prevalence of obesity, diabetes and high blood pressure. HFpEF is considered to be a systemic syndrome with diverse fanotypes, various pathophysiologies, and multiple comorbidities. The diagnosis of HFpEF is challenging and ultimately refers to the concept of heart failure as a clinical syndrome characterised by symptoms associated with a reduced ability of the heart to adequately pump blood at normal filling pressures during diastolic conditions. Previous clinical studies have been largely ineffective in determining effective HFpEF treatments, but there is evidence of the use of diuretics, mineral corticosteroid antagonists and lifestyle interventions. Based on the results of EMPEROR-PRESERVED study sodium-glucose cotransporter 2 inhibitors are recommended in HFpEF The pathophysiological diversity of HFpEF imaging is considerable and studies are currently being conducted to evaluate the optimal methods for classifying patients into phenotypically homogeneous subpopulations to allow better individualisation of treatment.